Repligen (RGEN) News Today → Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes) (Ad) Free RGEN Stock Alerts $156.75 -1.41 (-0.89%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 4:53 AM | marketbeat.comDimensional Fund Advisors LP Purchases 16,430 Shares of Repligen Co. (NASDAQ:RGEN)Dimensional Fund Advisors LP grew its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 301,968 shares of the biotechnology company's stock after purchasiMay 27 at 12:50 PM | marketbeat.comArtisan Partners Limited Partnership Has $273.79 Million Holdings in Repligen Co. (NASDAQ:RGEN)Artisan Partners Limited Partnership cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,522,743 shares of the biotechnoloMay 25 at 10:42 PM | marketbeat.comWestfield Capital Management Co. LP Buys 49,727 Shares of Repligen Co. (NASDAQ:RGEN)Westfield Capital Management Co. LP grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 20.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 294,222 shares of the biotechnology company's stock after purchasing an additional 49,72May 25 at 3:10 AM | americanbankingnews.comBrokers Issue Forecasts for Repligen Co.'s FY2024 Earnings (NASDAQ:RGEN)May 24, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) to Post FY2024 Earnings of $1.46 Per Share, Zacks Research ForecastsRepligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Zacks Research raised their FY2024 earnings estimates for shares of Repligen in a research note issued on Tuesday, May 21st. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earningMay 24, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 77.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,535 shares of the biotechnology company's stockMay 24, 2024 | insidertrades.comRepligen Co. (NASDAQ:RGEN) CEO Sells $3,377,314.72 in StockMay 23, 2024 | finance.yahoo.comInsider Sell: CEO Anthony Hunt Sells 20,072 Shares of Repligen Corp (RGEN)May 23, 2024 | americanbankingnews.comRepligen Co. Expected to Post Q3 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)May 23, 2024 | marketbeat.comQ3 2024 EPS Estimates for Repligen Co. (NASDAQ:RGEN) Reduced by Zacks ResearchRepligen Co. (NASDAQ:RGEN - Free Report) - Investment analysts at Zacks Research reduced their Q3 2024 earnings per share (EPS) estimates for shares of Repligen in a report released on Tuesday, May 21st. Zacks Research analyst R. Department now forecasts that the biotechnology company will post eMay 22, 2024 | marketbeat.comInsider Selling: Repligen Co. (NASDAQ:RGEN) CEO Sells 20,072 Shares of StockRepligen Co. (NASDAQ:RGEN - Get Free Report) CEO Anthony Hunt sold 20,072 shares of the company's stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the completion of the transaction, the chief executive officer now directly owns 163,177 shares of the company's stock, valued at $27,456,162.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website.May 22, 2024 | globenewswire.comRepligen Corporation to Present at Upcoming June Investor ConferencesMay 20, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Sold by Amalgamated BankAmalgamated Bank lowered its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 16.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,819 shares of the biotechnology company's stock after selling 5,536 sharesMay 18, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Stock Holdings Increased by Wafra Inc.Wafra Inc. boosted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 75.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,862 shares of the biotechnology company's stock after purchasinMay 16, 2024 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Position in Repligen Co. (NASDAQ:RGEN)Principal Financial Group Inc. raised its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 36.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 262,708 shares of the biotechnology company's stock afMay 15, 2024 | msn.comHere's Why Baron Discovery Fund Sold Repligen Corporation (RGEN)May 15, 2024 | finance.yahoo.comHere’s Why Baron Discovery Fund Sold Repligen Corporation (RGEN)May 10, 2024 | finance.yahoo.comWe Discuss Why Repligen Corporation's (NASDAQ:RGEN) CEO Compensation May Be Closely ReviewedMay 10, 2024 | marketbeat.comLos Angeles Capital Management LLC Buys New Position in Repligen Co. (NASDAQ:RGEN)Los Angeles Capital Management LLC purchased a new position in Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 5,368 shares of the biotechnology company's stock, valued at approximately $965,000. A number of oMay 9, 2024 | marketbeat.comTimesSquare Capital Management LLC Boosts Position in Repligen Co. (NASDAQ:RGEN)TimesSquare Capital Management LLC grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 61.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 205,883 shares of the biotechnology company's stock aftMay 7, 2024 | marketbeat.comLisanti Capital Growth LLC Sells 11,715 Shares of Repligen Co. (NASDAQ:RGEN)Lisanti Capital Growth LLC cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 82.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,425 shares of the biotechnology company's stock after selling 11,715 shares during the period. LisaMay 7, 2024 | globenewswire.comRepligen Corporation to Present at Upcoming May Investor ConferencesMay 6, 2024 | marketbeat.comInternational Assets Investment Management LLC Buys 58,299 Shares of Repligen Co. (NASDAQ:RGEN)International Assets Investment Management LLC lifted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 58,615 shares of the biotechnology compMay 4, 2024 | marketbeat.comVan ECK Associates Corp Has $8.37 Million Stake in Repligen Co. (NASDAQ:RGEN)Van ECK Associates Corp cut its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 14.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,536 shares of the biotechnology company's stock afMay 3, 2024 | finance.yahoo.comRepligen First Quarter 2024 Earnings: EPS Misses ExpectationsMay 3, 2024 | marketbeat.comRepligen Co. Expected to Post Q2 2024 Earnings of $0.33 Per Share (NASDAQ:RGEN)Repligen Co. (NASDAQ:RGEN - Free Report) - Equities research analysts at Leerink Partnrs increased their Q2 2024 earnings per share estimates for shares of Repligen in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst P. Souda now expects that the biotechnology company wilMay 2, 2024 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Issues Earnings ResultsRepligen (NASDAQ:RGEN - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The business had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The company's revenue was down 17.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 EPS.May 2, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. dropped their target price on shares of Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a report on Thursday.May 2, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings Call Transcript Highlights: Navigating Market Shifts and ...May 2, 2024 | gurufocus.comQ1 2024 Repligen Corp Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comRepligen Corp (RGEN) Q1 2024 Earnings: A Close Alignment with Analyst ProjectionsMay 1, 2024 | investorplace.comRGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024May 1, 2024 | marketbeat.comRepligen (NASDAQ:RGEN) Issues FY 2024 Earnings GuidanceRepligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance. The company provided EPS guidance of 1.420-1.490 for the period, compared to the consensus estimate of 1.460. The company also issued revenue guidance of $620.0 millionillion-$650.0 millionillion, compared to the consensus estimate of $635.6 millionillion.May 1, 2024 | msn.comRepligen reports mixed Q1 results; reaffirms FY24 outlookMay 1, 2024 | globenewswire.comRepligen Reports First Quarter 2024 Financial ResultsApril 29, 2024 | nasdaq.comRGEN Quantitative Stock AnalysisApril 24, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Stake Cut by New York State Common Retirement FundNew York State Common Retirement Fund cut its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 425,412 shares of the biotechnology company's stock after seApril 23, 2024 | finance.yahoo.comShould be Confident in Repligen Corporation (RGEN)’s Long-Term Growth Potential?April 19, 2024 | markets.businessinsider.comPositive Report for Repligen (RGEN) from Craig-HallumApril 19, 2024 | marketbeat.comFederated Hermes Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)Federated Hermes Inc. lowered its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 396,568 shares of the biotechnology company's stock after selling 49,325 shares duringApril 18, 2024 | nasdaq.comRepligen Corporation Common Stock (RGEN)April 17, 2024 | finance.yahoo.comRepligen to Report First Quarter 2024 Financial ResultsApril 17, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - RGENApril 16, 2024 | marketbeat.com14,600 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Louisiana State Employees Retirement SystemLouisiana State Employees Retirement System bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,600 shares of the biotechnologyApril 15, 2024 | marketbeat.comLondon & Capital Asset Management Ltd Acquires 6,215 Shares of Repligen Co. (NASDAQ:RGEN)London & Capital Asset Management Ltd boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,619 shares of the biotechnology company's stocApril 13, 2024 | marketbeat.comInternational Assets Investment Management LLC Grows Position in Repligen Co. (NASDAQ:RGEN)International Assets Investment Management LLC boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 18,449.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,615 shares of the biotechnology company's stock after purchasing anApril 12, 2024 | finance.yahoo.comArtisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share AppreciationApril 12, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Shares Bought by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 5.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,933 shares of the biotechnology comApril 12, 2024 | marketbeat.comRepligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from BrokeragesRepligen Co. (NASDAQ:RGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. Th Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Revealed: The Unknown Biotech Powering AI in Healthcare (Ad)The CEO of Google predicted this is "one of the most important things for humanity." We're standing at the brink of an AI revolution in medicine, a leap forward that will change the future medicine as we know it. If you're only watching tech giants like NVIDIA and Google for AI investments, you're missing the biggest opportunities... Because I've uncovered a little known biotech at the heart of this AI medical revolution. To discover the name and ticker of this hidden gem click here>>>> RGEN Media Mentions By Week RGEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGEN News Sentiment▼0.780.87▲Average Medical News Sentiment RGEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGEN Articles This Week▼215▲RGEN Articles Average Week Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Exelixis News Halozyme Therapeutics News Neurocrine Biosciences News Adaptive Biotechnologies News Biogen News Qiagen News Vaxcyte News Revolution Medicines News Bio-Techne News Krystal Biotech News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGEN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersRevealed: The Unknown Biotech Powering AI in HealthcareBehind the MarketsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
